Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.55 |
| ▸ | IKBKB | O14920 | 3/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CDK7 | P50613 | 2/20 | 0.50 |
| ▸ | CDK9 | P50750 | 2/20 | 0.50 |
| ▸ | CCNH | P51946 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA9 | Q16790 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 7/20 | 0.49 |
| ▸ | CA4 | P22748 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633147 | 0.83 | CDK1 (0.53) | CDK2IKBKBCCNT1CDK1CCNB1 | |
| SCHEMBL1634277 | 0.80 | SYK (0.52) | CDK2IKBKBCCNT1CDK1CCNB1 | |
| SCHEMBL1631112 | 0.79 | IKBKB (0.59) | CDK2CCNA2IKBKBCCNT1CDK1 | |
| SCHEMBL1632497 | 0.78 | AURKA (0.55) | CDK2CCNA2IKBKBCCNT1CDK1 | |
| SCHEMBL13498245 | 0.78 | CDK2 (0.48) | CDK2CCNA2CCNA1IKBKBCCNT1 | |
| SCHEMBL1634576 | 0.78 | IKBKB (0.58) | CDK2CCNA2IKBKBCCNT1CDK1 | |
| SCHEMBL1632977 | 0.77 | IKBKB (0.53) | CDK2CCNA2IKBKBCCNT1CDK1 | |
| SCHEMBL1633372 | 0.77 | IKBKB (0.53) | CDK2IKBKBCCNT1CDK1CCNB1 | |
| SCHEMBL1633248 | 0.77 | IKBKB (0.53) | CDK2IKBKBCCNT1CDK1CCNB1 | |
| SCHEMBL1633859 | 0.77 | CCNT1 (0.49) | CDK2IKBKBCCNT1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CDK2 29/4885CCNA2 731/4885CCNA1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.